Newsquawk Logo

Pfizer Inc. (PFE) Q4 2025 (USD): Adj. EPS 0.66 (exp. 0.58), Revenue 17.6bln (exp. 16.85bln); FY26 revenue view 59.5-62.5bln (exp. 61.94bln), FY26 EPS 2.80-3.00 (exp. 2.97)

Pfizer's Q4 2025 results exceeded expectations on both EPS and revenue, which is likely to bolster investor confidence in the company's growth trajectory.

Newsquawk StaffPublished On the live feed at — 8 more headlines followed before this page went public
Newsquawk headlinesUTC

US envoy Witkoff arrives in Israel

Pfizer (PFE) executive says obesity study results increase significantly Co's confidence in Phase 3 monthly dosing study set to launch this year; targeting the first of a series of potential obesity approvals in 2028

Pfizer Inc. (PFE) Q4 2025 (USD): Adj. EPS 0.66 (exp. 0.58), Revenue 17.6bln (exp. 16.85bln); FY26 revenue view 59.5-62.5bln (exp. 61.94bln), FY26 EPS 2.80-3.00 (exp. 2.97)

Ukraine's President Zelensky calls for additional support following discussion with NATO's Rutte

Pfizer (PFE) reported ultra-long-acting injectable GLP-1 RA shows robust and continued weight loss with monthly dosing in Phase 2b trial

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

Additionally, the FY26 revenue and EPS guidance ranges suggest a solid outlook, though the upper bounds are only slightly above consensus estimates, indicating cautious optimism rather than a robust upward revision. This performance could positively impact sentiment in the pharma sector and influence PFE's stock trajectory in the near term.

External

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.